ImmunityBio Statistics
Total Valuation
ImmunityBio has a market cap or net worth of $7.54 billion. The enterprise value is $8.14 billion.
Important Dates
The next estimated earnings date is Monday, May 11, 2026, before market open.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ImmunityBio has 1.03 billion shares outstanding. The number of shares has increased by 31.33% in one year.
| Current Share Class | 1.03B |
| Shares Outstanding | 1.03B |
| Shares Change (YoY) | +31.33% |
| Shares Change (QoQ) | +4.55% |
| Owned by Insiders (%) | 28.64% |
| Owned by Institutions (%) | 16.94% |
| Float | 384.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 66.55 |
| Forward PS | 35.28 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 71.86 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.10
| Current Ratio | 5.10 |
| Quick Ratio | 4.62 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.28 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -36.17% |
| Return on Invested Capital (ROIC) | -49.48% |
| Return on Capital Employed (ROCE) | -58.17% |
| Weighted Average Cost of Capital (WACC) | 5.17% |
| Revenue Per Employee | $163,948 |
| Profits Per Employee | -$508,535 |
| Employee Count | 691 |
| Asset Turnover | 0.26 |
| Inventory Turnover | 0.16 |
Taxes
| Income Tax | -135,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +146.62% in the last 52 weeks. The beta is 0.06, so ImmunityBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.06 |
| 52-Week Price Change | +146.62% |
| 50-Day Moving Average | 7.75 |
| 200-Day Moving Average | 3.83 |
| Relative Strength Index (RSI) | 46.20 |
| Average Volume (20 Days) | 26,013,031 |
Short Selling Information
The latest short interest is 134.20 million, so 12.99% of the outstanding shares have been sold short.
| Short Interest | 134.20M |
| Short Previous Month | 132.44M |
| Short % of Shares Out | 12.99% |
| Short % of Float | 34.94% |
| Short Ratio (days to cover) | 3.34 |
Income Statement
In the last 12 months, ImmunityBio had revenue of $113.29 million and -$351.40 million in losses. Loss per share was -$0.38.
| Revenue | 113.29M |
| Gross Profit | 112.54M |
| Operating Income | -256.03M |
| Pretax Income | -351.61M |
| Net Income | -351.40M |
| EBITDA | -240.60M |
| EBIT | -256.03M |
| Loss Per Share | -$0.38 |
Full Income StatementBalance Sheet
The company has $242.82 million in cash and $844.72 million in debt, with a net cash position of -$601.90 million or -$0.58 per share.
| Cash & Cash Equivalents | 242.82M |
| Total Debt | 844.72M |
| Net Cash | -601.90M |
| Net Cash Per Share | -$0.58 |
| Equity (Book Value) | -499.57M |
| Book Value Per Share | -0.49 |
| Working Capital | 253.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$304.94 million and capital expenditures -$3.85 million, giving a free cash flow of -$308.78 million.
| Operating Cash Flow | -304.94M |
| Capital Expenditures | -3.85M |
| Depreciation & Amortization | 15.43M |
| Net Borrowing | 1.72M |
| Free Cash Flow | -308.78M |
| FCF Per Share | -$0.30 |
Full Cash Flow StatementMargins
| Gross Margin | 99.34% |
| Operating Margin | -226.00% |
| Pretax Margin | -310.37% |
| Profit Margin | n/a |
| EBITDA Margin | -212.38% |
| EBIT Margin | -226.00% |
| FCF Margin | n/a |
Dividends & Yields
ImmunityBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -31.33% |
| Shareholder Yield | -31.33% |
| Earnings Yield | -4.66% |
| FCF Yield | -4.10% |
Analyst Forecast
The average price target for ImmunityBio is $12.57, which is 72.19% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.57 |
| Price Target Difference | 72.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 100.99% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ImmunityBio has an Altman Z-Score of -9.86 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.86 |
| Piotroski F-Score | 3 |
